ASSEMBLY BIOSCIENCES, INC.
No enriched coverage for $ASMB in the last 7 days.
No SEC Form 4 filings for $ASMB in the last 30 days.
See all $ASMB insider activity →Assembly Biosciences (ASMB) reported a decrease in Q1 revenue and a widening net loss. The article, sourced from Reuters and Refinitiv, provides a brief update on the company's financial performance.
Assembly Biosciences Inc. (ASMB) reported a first-quarter loss of $9.1 million, or 54 cents per share. The biotech company generated $8.2 million in revenue for the period. Despite the quarterly loss, Assembly Biosciences shares have more than doubled in value over the last 12 months, though they have seen a slight decrease of just over 8% since the beginning of the year.
Assembly Biosciences' Chief Medical Officer, Anuj Gaggar, was granted 26,000 Restricted Stock Units (RSUs) as part of his annual equity compensation. These RSUs will vest in four equal installments annually from March 29, 2027, through March 29, 2030, provided he remains with the company. This grant represents 65% of his annual equity award, with the remaining 35% contingent on stockholder approval of an increase in shares authorized under the company's 2018 stock incentive plan.
Assembly Biosciences reported a decline in Q1 revenue and a widened net loss, indicating potential operational or market challenges.
Assembly Biosciences reported a Q1 loss of $9.1 million, with revenue of $8.2 million. Despite the quarterly loss, the stock has more than doubled over the past year, though it declined slightly (~8%) since the start of the current year.
The Chief Medical Officer's (CMO) stock grant indicates confidence in the company's future prospects, potentially positive for stock sentiment.
The increase in CEO bonus target from 60% to 65% for fiscal 2026 indicates a management incentive alignment with company performance goals. This could signal management confidence but may also raise concerns about executive compensation levels.
Assembly Biosciences (NASDAQ:ASMB) has been upgraded to a 'Strong-Buy' following a quarterly earnings beat, indicating positive near-term momentum. Despite negative forecasts for the current fiscal year's EPS, the recent performance suggests potential for short-term gains.
alphai scores every news story that mentions ASMB with an AI model for sentiment and relevance, and aggregates insider trades from ASSEMBLY BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Assembly Biosciences (ASMB) reported a decrease in Q1 revenue and a widening net loss. The article, sourced from Reuters and Refinitiv, provides a brief update on the company's financial performance.
3 min readAssembly Biosciences Inc. (ASMB) reported a first-quarter loss of $9.1 million, or 54 cents per share. The biotech company generated $8.2 million in revenue for the period. Despite the quarterly loss, Assembly Biosciences shares have more than doubled in value over the last 12 months, though they have seen a slight decrease of just over 8% since the beginning of the year.
3 min readAssembly Biosciences' Chief Medical Officer, Anuj Gaggar, was granted 26,000 Restricted Stock Units (RSUs) as part of his annual equity compensation. These RSUs will vest in four equal installments annually from March 29, 2027, through March 29, 2030, provided he remains with the company. This grant represents 65% of his annual equity award, with the remaining 35% contingent on stockholder approval of an increase in shares authorized under the company's 2018 stock incentive plan.
2 min readAssembly Biosciences (ASMB) has adopted a new 2026 Corporate Bonus Plan, effective January 1, 2026, designed to motivate and reward employees with performance-based cash bonuses. The plan outlines varying target bonus opportunities, up to 75% of base salary for the CEO, and distinguishes between corporate and individual objectives. Notably, the Compensation Committee also increased CEO Jason A. Okazaki’s bonus target from 60% to 65% of his base salary for fiscal 2026.
2 min readWall Street Zen has upgraded Assembly Biosciences (NASDAQ:ASMB) from a "buy" to a "strong-buy," aligning with an overall "Moderate Buy" consensus despite mixed analyst opinions. This upgrade follows a significant beat in quarterly EPS and revenue, though negative EPS is still forecasted for the current fiscal year. The company's stock shows a market cap of $439.41 million, and institutional investors have been actively trading its shares.
3 min readAssembly Biosciences (NASDAQ: ASMB) has received a "Moderate Buy" consensus recommendation from seven research firms, with an average 12-month target price of $41.75. The biopharmaceutical company, focused on hepatitis B and D therapies, saw its shares open up 10.7% at $28.75. Institutional investors have significantly increased their stakes in the company, with hedge funds owning 19.92% of the stock.
3 min readAssembly Biosciences (Nasdaq: ASMB) announced positive interim results from two Phase 1b studies for its investigational long-acting HSV helicase-primase inhibitors, ABI-1179 and ABI-5366, for recurrent genital herpes. ABI-1179 50 mg weekly demonstrated a 98% reduction in HSV-2 shedding and a 91% reduction in virologically confirmed genital lesion rate. The ABI-5366 monthly cohort showed a 76% reduction in shedding and an 88% reduction in lesion rate, with both candidates generally well-tolerated.
3 min read- Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation -
2 min readFour biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
4 min readAssembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 min read
